ImmunoQs

ImmunoQs is a Singapore-based life-sciences company and a spin-off from the Agency for Science, Technology and Research (A*STAR), Singapore. It positions itself at the intersection of advanced spatial omics technologies, machine learning and immuno-oncology, with the stated mission of enhancing patient outcomes in modern cancer therapies. The company makes advanced spatial omics technologies and machine learning modeling more accessible to clinicians, scientists and drug developers, and its digital analytics platform is designed to help users make sense of highly complex and heterogeneous spatial omics data and discover new predictive biomarkers for targeted and immunotherapy. ImmunoQs offers a comprehensive suite of specialized services focused on spatial omics, immune monitoring and digital analytics, tailored to specific clinical needs and scientific questions in immuno-oncology. Its offering is organized around three themes. "Immuno Quantification" helps scientists design more predictive biomarker panels, perform large-scale spatial omics experiments, and quantify the spatial distributions of markers in the tumor microenvironment. "Immuno Cues" is the company's user-friendly digital analytics platform, enabling clinicians and scientists to visualize and explore large spatial omics datasets and discover cues that may predict immunotherapy responses. "Immuno Cure" covers collaboration with clinicians and drug developers to test biomarkers and machine-learning models in clinical trials and integrate them with current clinical workflows and patient care systems. The company's story began in 2019, when four A*STAR scientists with distinct backgrounds came together with complementary scientific and technological expertise and a shared vision to create a positive impact. The founding team comprises Loo Lit Hsin (Co-founder & Chief Executive Officer), Jeffrey Lim (Co-founder & Chief Technology Officer), Joey Lee (Co-founder & Chief Operations Officer) and Joe Yeong (Co-founder & Scientific Advisor). ImmunoQs states that its lab was officially operational on 1 September 2023, marking the start of a new chapter to make its technologies accessible to research and clinical communities across Singapore and the Asia Pacific region. As a private company, ImmunoQs operates primarily in Singapore and the wider Asia Pacific market, serving clinicians, scientists and drug developers. Its brand promise centers on personalized cancer care: the company believes every cancer patient is unique and deserves fully personalized care and treatment, and it aims to improve patients' quality of life through better predictive biomarkers and data-driven clinical decision support.

ImmunoQs is a spin-off company from the Agency for Science, Technology and Research (A*STAR), Singapore. Its core mission is to enhance patient outcomes in modern cancer therapies, and it offers comprehensive suites of specialized services to clinicians, scientists and drug developers, focusing on spatial omics, immune monitoring and digital analytics, meticulously tailored to address specific clinical needs and scientific questions in immuno-oncology. The company's story began in 2019, when four A*STAR scientists with distinct backgrounds came together to form a team with complementary scientific and technological expertise and a shared vision to create a positive impact. It was this mutual aspiration that marked the humble beginnings of ImmunoQs. The founding team consists of Loo Lit Hsin (Co-founder & Chief Executive Officer), Jeffrey Lim (Co-founder & Chief Technology Officer), Joey Lee (Co-founder & Chief Operations Officer) and Joe Yeong (Co-founder & Scientific Advisor). Fast-forwarding to 1 September 2023, the company's lab was officially operational and it embarked on a new chapter to make its technologies accessible and available to the vibrant research and clinical communities across Singapore and the Asia Pacific region. The company's public positioning since then has centered on three connected offerings: Immuno Quantification, Immuno Cues and Immuno Cure, which together span biomarker panel design, large-scale spatial omics experiments, digital analytics and clinical trial integration.

• 2023

  ImmunoQs lab officially becomes operational on 1 September 2023.

• 2019

  Four A*STAR scientists come together to form the founding team of ImmunoQs.

Provider of accessible advanced spatial omics and machine learning tools for immuno-oncology biomarker discovery, targeting clinicians, scientists and drug developers in Singapore and Asia Pacific.

• Immuno Quantification

  Helps scientists design more predictive biomarker panels, perform large-scale spatial omics experiments, and quantify the spatial distributions of markers in the tumor microenvironment.

• Immuno Cues

  A user-friendly digital analytics platform that enables clinicians and scientists to visualize and explore large spatial omics data and discover new cues that may predict immunotherapy responses.

• Immuno Cure

  Collaboration with clinicians and drug developers to test biomarkers and machine-learning models in clinical trials and integrate them with current clinical workflows and patient care systems.

1. 1ImmunoQs | Map the cues, Find the cures.immunoqs.com
2. 2ImmunoQs | Map the cues, Find the cures. (About)immunoqs.com
3. 3ImmunoQs (Singapore) - Wikidatawikidata.org